Fig-Derived Lactobacillus paracasei Composition for Cytokine Suppression

The patent applies preliminary action by using probiotics to modulate the immune system and gut microbiota before inflammation fully develops or recurs. The probiotics prepare the intestinal environment and immune response in advance, creating a protective effect that prevents relapse when conventional medications are discontinued. This is evidenced by the patent's description of probiotics preventing recurrence of inflammatory bowel disease by establishing a beneficial microbial balance that suppresses inflammation proactively.

The patent applies composite materials by combining multiple strains of probiotics (Lactobacillus casei, Lactobacillus plantarum, Lactobacillus acidophilus, Bifidobacterium longum, and Bifidobacterium breve) into a synergistic formulation. Each strain contributes different beneficial effects: L. casei and L. plantarum produce anti-inflammatory metabolites, L. acidophilus enhances gut barrier function, and Bifidobacterium species modulate immune responses. This composite probiotic approach achieves both high safety and enhanced effectiveness compared to single-strain probiotics.

The patent applies self-service by enabling the probiotics to autonomously maintain disease remission through continuous production of anti-inflammatory substances and modulation of the gut microbiota ecosystem. Once established, the probiotic formulation self-regulates the intestinal environment, producing metabolites like short-chain fatty acids and bacteriocins that continuously suppress inflammation without requiring external intervention or medication adjustments. This self-sustaining mechanism allows discontinuation of conventional medications while maintaining remission.